Mather Group LLC. Invests $142,000 in Laboratory Co. of America Holdings (NYSE:LH)

Mather Group LLC. bought a new position in shares of Laboratory Co. of America Holdings (NYSE:LH) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 626 shares of the medical research company’s stock, valued at approximately $142,000.

A number of other institutional investors have also modified their holdings of the stock. Manchester Capital Management LLC increased its position in shares of Laboratory Co. of America by 1.1% during the fourth quarter. Manchester Capital Management LLC now owns 4,159 shares of the medical research company’s stock worth $945,000 after acquiring an additional 45 shares during the period. Trust Investment Advisors increased its holdings in Laboratory Co. of America by 1.8% during the fourth quarter. Trust Investment Advisors now owns 2,567 shares of the medical research company’s stock valued at $583,000 after buying an additional 46 shares during the period. SP Asset Management LLC increased its holdings in Laboratory Co. of America by 0.3% during the fourth quarter. SP Asset Management LLC now owns 14,992 shares of the medical research company’s stock valued at $3,407,000 after buying an additional 46 shares during the period. Atria Wealth Solutions Inc. increased its holdings in Laboratory Co. of America by 2.8% during the fourth quarter. Atria Wealth Solutions Inc. now owns 1,969 shares of the medical research company’s stock valued at $448,000 after buying an additional 53 shares during the period. Finally, Wahed Invest LLC increased its holdings in Laboratory Co. of America by 3.9% during the fourth quarter. Wahed Invest LLC now owns 1,443 shares of the medical research company’s stock valued at $328,000 after buying an additional 54 shares during the period. 95.94% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LH shares. StockNews.com lowered shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a report on Tuesday, June 4th. Leerink Partnrs reissued an “outperform” rating on shares of Laboratory Co. of America in a report on Monday, February 26th. Robert W. Baird cut their price objective on shares of Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating on the stock in a report on Friday, April 26th. JPMorgan Chase & Co. cut their price target on shares of Laboratory Co. of America from $261.00 to $243.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. Finally, Argus raised shares of Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price target on the stock in a report on Monday, March 25th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Laboratory Co. of America presently has a consensus rating of “Moderate Buy” and an average target price of $241.86.

Insider Transactions at Laboratory Co. of America

In related news, COO Mark S. Schroeder sold 6,477 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $217.29, for a total transaction of $1,407,387.33. Following the completion of the transaction, the chief operating officer now directly owns 5,036 shares in the company, valued at $1,094,272.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Mark S. Schroeder sold 6,477 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $217.29, for a total transaction of $1,407,387.33. Following the completion of the transaction, the chief operating officer now directly owns 5,036 shares in the company, valued at $1,094,272.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Der Vaart Sandra D. Van sold 3,553 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $216.74, for a total transaction of $770,077.22. Following the transaction, the executive vice president now owns 7,637 shares of the company’s stock, valued at $1,655,243.38. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,469 shares of company stock worth $3,959,058. Company insiders own 0.85% of the company’s stock.

Laboratory Co. of America Trading Up 0.4 %

NYSE:LH opened at $207.38 on Friday. Laboratory Co. of America Holdings has a 12 month low of $191.02 and a 12 month high of $234.09. The firm has a fifty day simple moving average of $201.84 and a 200-day simple moving average of $213.48. The company has a current ratio of 0.88, a quick ratio of 0.76 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $17.48 billion, a P/E ratio of 41.73, a PEG ratio of 1.55 and a beta of 1.04.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, topping the consensus estimate of $3.48 by $0.20. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The business had revenue of $3.18 billion during the quarter, compared to the consensus estimate of $3.12 billion. During the same period in the previous year, the firm posted $3.82 earnings per share. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, equities research analysts anticipate that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th were paid a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, May 24th. This represents a $2.88 annualized dividend and a dividend yield of 1.39%. Laboratory Co. of America’s payout ratio is currently 57.95%.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).